Groundbreaking investigations emerging from Dartmouth Cancer Center (DCC) have illuminated a potentially transformative role for a widely recognized cardiovascular medication in the realm of oncology, suggesting that a drug routinely prescribed to manage elevated blood pressure could significantly enhance the potency of a crucial category of cancer treatments. This research, detailed in a recent publication within The Journal for ImmunoTherapy of Cancer, demonstrates that telmisartan, an FDA-approved pharmaceutical, demonstrably amplifies the tumor-annihilating capabilities of olaparib, a targeted therapy. The implications of these findings are substantial, hinting at the possibility of extending the benefits of advanced cancer interventions to a broader patient demographic.
The core of this discovery lies in understanding the mechanism by which olaparib operates. Olaparib is classified as a PARP inhibitor, a class of drugs designed to exploit specific vulnerabilities within cancer cells’ DNA repair pathways. These agents are particularly effective against malignancies characterized by deficiencies in homologous recombination repair, a critical process for fixing double-strand DNA breaks. This deficiency is frequently observed in cancers associated with inherited genetic predispositions, such as mutations in the BRCA1 and BRCA2 genes. By inhibiting PARP enzymes, which are essential for repairing single-strand DNA breaks, these drugs can indirectly lead to the accumulation of double-strand breaks that cancer cells with compromised homologous recombination repair cannot effectively mend, ultimately triggering cell death.
However, a significant limitation of PARP inhibitors is their efficacy is often contingent on the presence of these specific DNA repair defects. Many tumors, even those initially responsive, can develop resistance over time, rendering the treatment ineffective. This inherent limitation means a considerable proportion of cancer patients do not derive benefit from these cutting-edge therapies. The Dartmouth team’s breakthrough lies in their observation that telmisartan can re-sensitize tumors to PARP inhibitors, even in the absence of the typical DNA repair weaknesses that these drugs normally target. This suggests a novel strategy to overcome inherent or acquired resistance.
Preclinical experimental models provided compelling evidence for this synergistic effect. When telmisartan was administered concurrently with olaparib, researchers observed a marked increase in DNA damage within cancer cells. Crucially, this cellular damage was accompanied by a robust activation of the body’s own immune defenses. The combination therapy stimulated the production of type I interferons, a family of signaling proteins that play a pivotal role in alerting the immune system to the presence of cancerous cells and orchestrating an attack. This immune potentiation, according to the study’s senior and lead author, Tyler J. Curiel, MD, MPH, FACP, appears to be a central driver of the enhanced therapeutic outcome.
What sets telmisartan apart within its therapeutic class is its distinctive impact on the tumor microenvironment and immune signaling. Telmisartan belongs to the angiotensin II receptor blocker (ARB) family of medications, widely prescribed for hypertension. However, comparative analyses conducted by the Dartmouth researchers revealed that telmisartan’s capacity to augment anti-cancer therapies is unique among other ARBs. This suggests that its beneficial effects are not merely a class-wide property but rather a specific characteristic of this particular molecule.
Beyond its immune-boosting properties, telmisartan demonstrated another significant advantage: it effectively reduced the expression of PD-L1 within tumor cells. PD-L1 (programmed death-ligand 1) is a protein that many cancers exploit as a shield, presenting itself to immune cells in a way that signals them to stand down, thereby evading immune surveillance. By diminishing PD-L1 levels, telmisartan potentially renders tumors more visible and vulnerable to immune-mediated destruction, offering an additional layer of therapeutic benefit when combined with targeted agents. Dr. Curiel elaborated that telmisartan possesses several distinct anticancer properties that, in concert with targeted therapies, could render tumors more susceptible to various treatment modalities. While the current study focused on PARP inhibitors, the researchers also possess substantial data indicating telmisartan’s ability to enhance the efficacy of different chemotherapy regimens and immunotherapies across a spectrum of cancer types, mediated through related biological pathways.
The established safety profile, oral administration route, and excellent tolerability of telmisartan, even in individuals without hypertension, make it an ideal candidate for expedited evaluation in cancer patients. Recognizing this potential, Dr. Curiel and his colleagues at DCC have proactively initiated two clinical trials to rigorously assess the efficacy of this combination therapy.
One of these trials is currently investigating the effects of combining telmisartan with olaparib in men diagnosed with metastatic, castration-resistant prostate cancer. Early indications from this study are highly encouraging, with the first participant reportedly experiencing an exceptional response to the treatment regimen. A second trial, designed to evaluate the same combination in patients with platinum-resistant ovarian cancer, has also recently enrolled its inaugural participant. The research team’s overarching objective is to ascertain whether this integrated therapeutic approach can lead to improved outcomes for a greater number of patients, enabling them to derive more benefit from PARP inhibitors and other cancer treatment classes, and potentially overcoming the challenge of treatment resistance. The advancement of this critical research and the subsequent launch of these vital clinical trials were made possible through the generous support provided by the Guyre fund and the Gmelich fund at Dartmouth Cancer Center.
About the Author
